Niagen Bioscience Inc. reported Q4 2025 net sales of $33.8 million, up 16% YoY, and full year 2025 net sales of $129.4 million, up 30% YoY, with net income of $17.4 million and $64.8 million in cash. The company provided 2026 net sales outlook of 10-15% growth excluding the sold reference standards segment and highlighted recent asset sale, IP acquisition, and product launches.
Key takeaways
Full year 2025 net sales $129.4M, +30% YoY; Tru Niagen® $97.7M, +27%; Niagen ingredient $27.9M, +45%
Q4 2025 net sales $33.8M, +16% YoY; gross margin 64.1%, +160 bps; net income $4.1M
Full year 2025 net income $17.4M, +103% YoY; Adjusted EBITDA $20.4M, +139% YoY; basic EPS $0.22
Cash $64.8M at Dec 31, 2025 vs $44.7M at Dec 31, 2024; operating cash flow $13.5M
Sold analytical reference standards assets Feb 2026 for ~$6.0M cash; acquired NR patent portfolio Dec 2025 from Queen’s University Belfast
2026 net sales outlook 10-15% growth excluding reference standards segment